+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Trends in cytomegalovirus infection rate in liver transplant recipients and correlation with evolving recipient and donor characteristics



Trends in cytomegalovirus infection rate in liver transplant recipients and correlation with evolving recipient and donor characteristics



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 500



Background: To determine whether recipient and donor characteristics that influence CMV infection rate after liver transplantation have changed. Methods: Recipient and donor characteristics (and other variables) that may affect CMV infection rate were assessed in 232 liver transplant recipients at our institution over a 14-year period (1989-2003). Chi square was used for trend analyses. Results: Since 1989, the age of the recipients (p=.0001) and that of the donors (p=.0001) has increased. Pretransplant CMV seropositivity in the recipients has decreased significantly (p=.0001, from 86.4% from 1989-92 to 53.7% from 2000-03) whereas donor CMV seropositivity has remained unchanged (p>0.20). As a result, there has been a significant increase in the proportion of high-risk (R-/D+) patients (p=.012); 10.6% of the recipients between 1989-92 vs. 24.1% between 2000-03 were R-/D+. The Child-Pugh scores of the recipients have remained unchanged over time. However, the proportion of patients transplanted while in the ICU has decreased significantly over time (p=.0002). The latter may have been a surrogate for lower pretransplant transfusion requirements and therefore lower CMV seropositivity in the recipients. A significant decrease in rejection rate and a trend towards an increase in CMV infection rate has occurred over time (p=.094). The incidence of CMV disease however, has decreased significantly (p=.0004, from 18.2% in 1989-92 to 0% in 2000-03) due largely to employment of preemptive therapy upon detection of asymptomatic antigenemia in the later years (prophylaxis for CMV infection has not been employed). Conclusions: The proportion of high-risk patients (CMV recipient-/donor+) has increased significantly over time, attributable largely to a declining rate of CMV seropositivity in the recipients prior to transplantation. These data have implications for guiding prophylactic practices and resource utilization after liver transplantation.

(PDF emailed within 1 workday: $29.90)

Accession: 035985296

Download citation: RISBibTeXText


Related references

Impact of evolving trends in recipient and donor characteristics on cytomegalovirus infection in liver transplant recipients. Transplantation 77(1): 106-110, 2004

Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transplant Infectious Disease 12(6): 473-479, 2011

Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir. Transplantation Proceedings 50(1): 124-129, 2018

Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transplant Infectious Disease 17(2): 163-173, 2016

Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience. Transplant Infectious Disease 20(4): E12905, 2018

Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients. International Journal of Infectious Diseases 65: 50-56, 2017

Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis. Journal of Infectious Diseases 2019, 2019

Is there an association between cmv infection donor recipient hla phenotype matching and vanishing bile duct syndrome in liver transplant recipients. Hepatology 10(4): 665, 1989

Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transplantation 14(2): 240-244, 2008

Contrast patterns of Cytomegalovirus and Epstein-Barr virus infection in pediatric living-donor liver transplant recipients. Experimental and Clinical Transplantation 13 Suppl 1: 75-82, 2016

Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions. Boston Center for Liver Transplantation CMVIG Study Group. Clinical Infectious Diseases 23(2): 292-297, 1996

Cytomegalovirus Treatment Strategy After a Liver Transplant: Preemptive Therapy or Prophylaxis for Cytomegalovirus Seropositive Donor and Recipient. Experimental and Clinical Transplantation 14(4): 419-423, 2017

Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients. Transplant Infectious Disease 20(5): E12964, 2018

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. Journal of Heart and Lung Transplantation 29(9): 1014-1020, 2010

Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients. Transplant Infectious Disease 2018: E13015, 2018